Healthpeak Properties has quietly staged a comeback, riding a renewed bid for defensive yield. But after a volatile year, are investors being paid enough for the risks ahead?
Healthcare real estate was out of fashion for much of the past two years. Rising rates, pandemic hangovers in medical office usage, and a harsh de-rating of real estate investment trusts (REITs) all weighed on valuations. Now the pendulum is swinging back, and Healthpeak Properties stock is emerging as one of the clearer barometers of that shift.
Traded on the New York Stock Exchange under the ticker PEAK, Healthpeak Properties is a large U.S. healthcare REIT with a portfolio focused on life science campuses, medical office buildings, and senior housing. Over the past week, its shares have inched higher in relatively steady trading, extending a broader recovery that began in the autumn. The five-day price action has been mildly positive rather than euphoric, suggesting that the fast-money short-covering phase is over and longer-term investors are starting to re-underwrite the story.
Over the past 90 days, Healthpeak stock has advanced meaningfully from its early-quarter lows, roughly tracking the broader REIT sector’s bounce as bond yields eased and markets became more confident that the U.S. Federal Reserve is either at or near the peak of its tightening cycle. The move has pulled the stock away from its 52-week low, set when investors were pricing in a bleaker macro backdrop and more pain from higher financing costs. Still, Healthpeak trades well below its 52-week high, underscoring how severely the entire listed real estate complex had been discounted.
The message from the tape is clear: sentiment has shifted from outright bearish to cautiously bullish. The rally is no longer a pure rates trade; it is becoming a test of whether Healthpeak’s operational fundamentals and portfolio mix justify a continued re-rating.
Learn more about Healthpeak Properties and its healthcare-focused real estate portfolio
For investors who stayed the course, the past year has been a lesson in both pain and patience. Healthpeak Properties’ share price one year ago sat meaningfully below today’s level, reflecting the deep skepticism then surrounding rate-sensitive assets. From that starting point, the stock has delivered a solid positive return, with a double-digit percentage gain in price when measured against the latest close.
Layer in the REIT’s dividend distributions, and the total shareholder return over the period improves further. Income remains a critical component of the investment case: Healthpeak continues to pay out an attractive dividend yield compared with Treasury benchmarks, even after the bond sell-off reset the risk-free rate higher. Investors who bet on Healthpeak Properties a year ago represent a cohort that effectively leaned into fear around higher rates and came out ahead as the market began to reassess the durability of healthcare real estate cash flows.
That said, the recovery is still incomplete. Long-term holders who bought near the stock’s 52-week high remain underwater, and the chart over a multi-year horizon still shows a sizable gap between today’s levels and pre-rate-hike peaks. The one-year gain is therefore less an all-clear signal and more an indication that the worst of the de-rating may be behind the company — provided fundamentals keep cooperating.
In recent days, the news flow around Healthpeak has been concentrated on portfolio optimization and the integration of prior strategic moves rather than splashy new acquisitions. Earlier this year, the company completed a major simplification and refocusing of its portfolio, doubling down on life science and medical office assets in core coastal markets while pruning non-core holdings. The market’s gradual appreciation of that strategy now appears to be a key driver behind the stock’s steadier tone.
Earlier this week, commentary from management and sector peers reinforced the view that leasing momentum in life science facilities is stabilizing after a period of slower demand. While the biotech funding environment remains selective, established tenants with strong balance sheets are still committing to quality space. That is crucial for Healthpeak, whose life science campuses in markets such as Boston and San Diego anchor its growth narrative. In medical office, rent collections remain strong and occupancy trends are resilient, a stark contrast to the pressures buffeting traditional office landlords. On the senior housing front, operators continue to report improving occupancy and pricing power as supply remains constrained and demographics steadily work in their favor.
Against that backdrop, the absence of negative surprises has itself become a quiet catalyst. With no major guidance cuts or unexpected impairments hitting headlines in the last week or two, investors have been free to focus on the underlying cash-flow durability. Trading volumes have not signaled speculative mania, but they indicate a healthy level of institutional participation, consistent with a stock transitioning from recovery trade to income-and-growth compounder.
On Wall Street, the consensus view on Healthpeak Properties has firmed into a moderate buy stance. Over the past month, several major sell-side firms have reiterated positive to neutral ratings on the stock, balancing the still-challenging macro environment with the defensive qualities of healthcare real estate.
Large banks and research houses generally slot Healthpeak into the
